Compare ECF & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | VYGR |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 194.0M |
| IPO Year | N/A | 2015 |
| Metric | ECF | VYGR |
|---|---|---|
| Price | $11.96 | $3.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 36.6K | ★ 527.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.77 |
| P/E Ratio | $25.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.15 | $2.65 |
| 52 Week High | $12.65 | $5.55 |
| Indicator | ECF | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 47.48 |
| Support Level | $11.74 | $2.79 |
| Resistance Level | $11.98 | $3.73 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 15.62 | 54.65 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.